Nolan Townsend, Lexeo Therapeutics CEO
July 15, 2024 07:41 AM EDTUpdated July 16, 12:46 PM
R&D
Cell/Gene Tx

Up­dat­ed: Lex­eo Ther­a­peu­tic­s' gene ther­a­py shows po­ten­tial for Friedre­ich's atax­ia car­diomy­opa­thy with ear­ly da­ta

Katherine Lewin

News Reporter

Lex­eo Ther­a­peu­tics thinks its gene ther­a­py has the po­ten­tial for ac­cel­er­at­ed ap­proval fol­low­ing pos­i­tive in­ter­im da­ta from two ear­ly-stage stud­ies,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times